Table: diabetes_ndcs_wac_increases_5_year_history , manufacturer_name like E*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

year_str	oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
2020	Rx0000114	Eli Lilly and Company	03/31/2020	00002143380	TRULICITY™ 0.75 mg/0.5 mL carton of 4 single-dose pens	01/31/2020	37.90	797.30	12/27/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All information is provided by Eli Lilly and Company ("Lilly") to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. The reported patent expiration information relates to only one or more compound patents covering TRULICITY™ and does not reflect pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of TRULICITY™. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available. This product was not acquired within the last 5 years, therefore columns 14-21 are intentionally left blank.
2020	Rx0000114	Eli Lilly and Company	03/31/2020	00002143480	TRULICITY™ 1.5 mg /0.5mL carton of 4 single-dose pens	01/31/2020	37.90	797.30	12/27/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All information is provided by Eli Lilly and Company ("Lilly") to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. The reported patent expiration information relates to only one or more compound patents covering TRULICITY™ and does not reflect pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of TRULICITY™. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available. This product was not acquired within the last 5 years, therefore columns 14-21 are intentionally left blank.